Advice
in the absence of a submission from the holder of the marketing authorisation:
vandetanib (Caprelsa®) is not recommended for use within NHS Scotland.
Indication under review: treatment of aggressive and symptomatic medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHS Scotland.
Download detailed advice39KB (PDF)
Medicine details
- Medicine name:
- vandetanib (Caprelsa)
- SMC ID:
- 797/12
- Indication:
- Treatment of aggressive and symptomatic medullary thyroid cancer (MTC) in patients with unresectable locally advanced or metastatic disease.
- Pharmaceutical company
- AstraZeneca UK Ltd
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 11 June 2012